OPKO Health Expands Collaboration Agreement with Entera Bio
OPKO Health (OPK), through its wholly owned subsidiary, OPKO Biologics, and Entera Bio (ENTX), announced the expansion of their 2025 Collaboration and License Agreement to advance the first oral long-acting PTH analog as a once-daily tablet for patients with hypoparathyroidism. The additional program combines OPKO's proprietary long-acting PTH variants with Entera's proprietary N-Tab technology. Following favorable pharmacodynamic and pharmacokinetic data reported in December 2025, the companies have jointly decided to accelerate development and expect to file an IND application with the U.S. Food and Drug Administration in late 2026. Under the expanded collaboration agreement, OPKO and Entera will each hold a 50% pro-rata ownership interest in the LA-PTH hypoparathyroidism program and will each be responsible for 50% of the program's development costs. The companies maintain their previously announced 60%/40% ownership structure and cost-sharing arrangement for the oral OXM program for metabolic and fibrotic disorders.
